How to buy Kodiak Sciences stock - 22 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kodiak Sciences stock

Own Kodiak Sciences stock in just a few minutes.

Kodiak Sciences Inc is a biotechnology business based in the US. Kodiak Sciences shares (KOD) are listed on the NASDAQ and all prices are listed in US Dollars. Kodiak Sciences employs 72 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Kodiak Sciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KOD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kodiak Sciences share price

Use our graph to track the performance of KOD stocks over time.

Kodiak Sciences shares at a glance

Information last updated 2021-04-16.
52-week range$42.97 - $171.21
50-day moving average $119.69
200-day moving average $121.45
Wall St. target price$138.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.50

Buy Kodiak Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kodiak Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kodiak Sciences financials

Gross profit TTM $0
Return on assets TTM -11.92%
Return on equity TTM -22.07%
Profit margin 0%
Book value $16.96
Market capitalisation $5.9 billion

TTM: trailing 12 months

Shorting Kodiak Sciences shares

There are currently 3.3 million Kodiak Sciences shares held short by investors – that's known as Kodiak Sciences's "short interest". This figure is 0.2% up from 3.3 million last month.

There are a few different ways that this level of interest in shorting Kodiak Sciences shares can be evaluated.

Kodiak Sciences's "short interest ratio" (SIR)

Kodiak Sciences's "short interest ratio" (SIR) is the quantity of Kodiak Sciences shares currently shorted divided by the average quantity of Kodiak Sciences shares traded daily (recently around 328788.35143139). Kodiak Sciences's SIR currently stands at 10.13. In other words for every 100,000 Kodiak Sciences shares traded daily on the market, roughly 10130 shares are currently held short.

However Kodiak Sciences's short interest can also be evaluated against the total number of Kodiak Sciences shares, or, against the total number of tradable Kodiak Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kodiak Sciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Kodiak Sciences shares in existence, roughly 70 shares are currently held short) or 0.1088% of the tradable shares (for every 100,000 tradable Kodiak Sciences shares, roughly 109 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kodiak Sciences.

Find out more about how you can short Kodiak Sciences stock.

Kodiak Sciences share dividends

We're not expecting Kodiak Sciences to pay a dividend over the next 12 months.

Kodiak Sciences share price volatility

Over the last 12 months, Kodiak Sciences's shares have ranged in value from as little as $42.97 up to $171.21. A popular way to gauge a stock's volatility is its "beta".

KOD.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kodiak Sciences's is 1.381. This would suggest that Kodiak Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kodiak Sciences overview

Kodiak Sciences Inc. , a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site